Abstract 144P
Background
Paclitaxel is commonly used as second-line therapy in advanced gastric cancer (AGC). The decision to proceed with second-line chemotherapy and select a chemotherapy regimen may be critical in vulnerable AGC patients after progression with first-line chemotherapy. However, there are no predictive biomarkers to identify patients with AGC who benefit from paclitaxel-based chemotherapy.
Methods
This study included 288 patients with AGC receiving second-line paclitaxel-based chemotherapy between 2017 and 2022 from K-MASTER project, a nationwide, government-funded precision medicine initiative. The data included clinicogenomic factors: clinical (age [young-onset vs. others], sex, histology [intestinal vs. diffuse type], prior trastuzumab use, duration of first-line chemotherapy, etc.) and genomic factors (pathogenic or likely pathogenic variants). The data were randomly divided into training and test sets (0.8:0.2). Three machine-learning methods, including random forest (RF), logistic regression (LR), and artificial neural network with genetic embedding (ANN) models, were used to develop the prediction model and were validated in the test sets.
Results
The median age was 64 years (range, 25-91) and 65.6% were male. A total of 288 patients were divided into training (n=230) and test sets (n=58). There were no significant differences in baseline characteristics between training and test sets. In the training set, the AUC for prediction of progression-free survival (PFS) with paclitaxel-based chemotherapy was 0.51, 0.73, and 0.75 in RF, LR, and ANN models, respectively. In the test set, the Kaplan-Meier curves of PFS were separated according to the three models: 2.8 vs. 1.5 months (P=0.07) in RF, 2.3 vs. 6.5 months (P=0.07) in LR, and 2.1 vs. 7.6 months (P=0.02) in ANN models.
Conclusions
These machine-learning models integrated clinical and genomic factors and can guide the selection of patients with AGC with a greater likelihood of a benefit from second-line paclitaxel-based chemotherapy. Further studies are necessary to validate and update these models in independent datasets in future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract